<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A3621</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 3621 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED FEBRUARY 12, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman  CAROL A. MURPHY</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Prohibits excessive increases in prices charged for
essential off-patent and generic prescription drugs and biological products. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As introduced.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning pharmaceutical pricing and
supplementing Title 24 of the Revised Statutes.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    As used in P.L.    ,
c.    (C.        ) (pending before the Legislature as this bill):</p>

<p class=MsoNormal style='line-height:150%'>     Director means the Director
of the Division of Consumer Affairs in the Department of Law and Public Safety.</p>

<p class=MsoNormal style='line-height:150%'>     Division means the Division
of Consumer Affairs in the Department of Law and Public Safety.</p>

<p class=MsoNormal style='line-height:150%'>     Essential off-patent or
generic drug or biological product means any prescription drug or biological
product, including any drug-device or biological product-device combination
product for the delivery of the prescription drug or biological product: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   that is made available
for sale in the State; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   for which all exclusive
marketing rights, if any, granted under the 52 Stat. 1040, 21 U.S.C. s.301 et
seq., section 351 of the &quot;Public Health Service Act,&quot; 58 Stat. 682,
42 U.S.C. s.262, and federal patent law, have expired;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   that is actively
manufactured and marketed by three or fewer manufacturers; and </p>

<p class=MsoNormal style='line-height:150%'>     (4)   that appears on the
current Model List of Essential Medicines adopted by the World Health
Organization or has been designated by the Commissioner of Health as an
essential medicine due to its efficacy in treating a life-threatening health
condition or a chronic health condition that substantially impairs a persons
ability to engage in activities of daily living.</p>

<p class=MsoNormal style='line-height:150%'>     FDA means the federal Food
and Drug Administration.</p>

<p class=MsoNormal style='line-height:150%'>     Price gouging means any
unconscionable increase in the price of a prescription drug or biological
product.</p>

<p class=MsoNormal style='line-height:150%'>     Unconscionable increase
means an increase in the price of a prescription drug or biological product
that:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   is excessive and not
justified by the cost of producing the drug or biological product or the cost
of appropriate expansion of access to the drug or biological product to promote
the public health; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   results in consumers for
whom the drug or biological product has been prescribed having no alternative
but to purchase the drug or biological product at an excessive price because of
the importance of the drug to the health of the consumers and insufficient
competition in the market for the drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>     Wholesale acquisition cost means<span
style='letter-spacing:0pt'>, with respect to a drug </span>or biological
product<span style='letter-spacing:0pt'>, the manufacturer's list price for the
drug </span>or biological product<span style='letter-spacing:0pt'> to
wholesalers or direct purchasers in the United States, not including prompt pay
or other discounts, rebates, or reductions in price, for the most recent month
for which the information is available, as reported in wholesale price guides
or other publications of drug </span>or biological product<span
style='letter-spacing:0pt'> pricing data.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  A prescription drug
or biological product manufacturer or wholesale distributor shall not engage in
price gouging in the sale of an essential off-patent or generic drug or
biological product.  </p>

<p class=MsoNormal style='line-height:150%'>      b.   It shall not constitute
a violation of subsection a. of this section for a wholesale distributor to
increase the price of an essential off-patent or generic drug or biological
product if the price increase is directly attributable to additional costs for
the drug or biological product imposed on the wholesale distributor by the
manufacturer of the drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>      3.   a.  The director may
notify the Attorney General of any increase in the price of an essential
off-patent or generic drug or biological product whenever: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   the price increase, individually
or in combination with other price increases:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   would result in an
increase of 50 percent or more in the wholesale acquisition cost of the drug or
biological product within the preceding one-year period; or</p>

<p class=MsoNormal style='line-height:150%'>     (b)   would result in an
increase of 50 percent or more in the price paid by the Medicaid program or NJ
FamilyCare program for the drug or biological product within the preceding
one-year period, as certified by the Director of the Division of Medical
Assistance and Health Services in the Department of Human Services; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   (a)  a 30-day supply of
the maximum recommended dosage of the drug or biological product for any
indication, according to the FDA-approved label for the drug or biological
product, would cost more than $80 at the wholesale acquisition cost of the drug
or biological product;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   a full course of
treatment with the drug or biological product, according to the FDA-approved
label for the drug or biological product, would cost more than $80 at the
wholesale acquisition cost of the drug or biological product; or</p>

<p class=MsoNormal style='line-height:150%'>     (c)   if the drug or
biological product is made available to consumers only in quantities that do
not correspond to a 30-day supply, a full course of treatment, or a single
dose, the drug or biological product would cost more than $80 at the wholesale
acquisition cost of the drug or biological product to obtain a 30-day supply or
a full course of treatment.</p>

<p class=MsoNormal style='line-height:150%'>      b.   At the request of the
Attorney General, the manufacturer of an essential off-patent or generic drug
or biological product identified in a notice provided pursuant to subsection a.
of this section shall, no later than 45 days after receipt of the request,
submit a statement to the Attorney General:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   itemizing the components
of the cost of producing the drug or biological product;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   identifying the
circumstances and timing of any increase in materials or manufacturing costs
that caused any increase in the price of the drug or biological product within
the one-year period preceding the date of the price increase;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   identifying the
circumstances and timing of any expenditures made by the manufacturer to expand
access to the drug or biological product and explaining any improvement in
public health associated with those expenditures; and</p>

<p class=MsoNormal style='line-height:150%'>     (4)   providing any other
information that the manufacturer believes to be relevant to a determination as
to whether a violation of P.L.    , c.    (C.        ) (pending before the
Legislature as this bill) has occurred.</p>

<p class=MsoNormal style='line-height:150%'>      c.    The Attorney General
may require a manufacturer or a wholesale distributor to produce any records or
documents that may be relevant to a determination as to whether a violation of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;(pending
before the Legislature as this bill) has occurred.</p>

<p class=MsoNormal style='line-height:150%'>      d.   Upon petition of the
Attorney General, a court may issue an order:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   compelling a
manufacturer to submit the statement required pursuant to subsection b. of this
section or a manufacturer or wholesale distributor to produce specific records
or documents as requested by the Attorney General pursuant to subsection c. of
this section;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   restraining or enjoining
a violation of P.L.    , c.    (C.        ) (pending before the Legislature as
this bill);</p>

<p class=MsoNormal style='line-height:150%'>     (3)   restoring to any
consumer, including any third party payor, any money acquired by a manufacturer
or wholesale distributor as a result of a price increase that violates P.L.   
, c.    (C.        ) (pending before the Legislature as this bill);</p>

<p class=MsoNormal style='line-height:150%'>     (4)   requiring a manufacturer
that has engaged in price gouging in the sale of an essential off-patent or
generic drug or biological product to make the drug or biological product
available to wholesale distributors, pharmacies, and consumers in the State,
for a period of up to one year, at a price that does not exceed the price at
which the drug or biological product was made available to such wholesale
distributors, pharmacies, and consumers immediately prior to the violation of
P.L.    , c.    (C.        ) (pending before the Legislature as this bill); and</p>

<p class=MsoNormal style='line-height:150%'>     (5)   assessing a civil
penalty of up to $10,000 against a manufacturer or wholesale distributor for
each violation of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;(pending
before the Legislature as this bill).  For the purposes of this paragraph, each
sale of an essential off-patent or generic drug or biological product at a
price that constitutes price gouging shall be deemed to be a separate
violation.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The Attorney General
shall not commence an action seeking relief pursuant to paragraphs (2) through
(5) of subsection d. of this section unless the Attorney General has provided
the manufacturer or wholesale distributor an opportunity to meet with the
Attorney General to provide a justification for the increase in the price of
the essential off-patent or generic drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>     f.     Any information provided
by a manufacturer pursuant to subsection b. of this section, or by a
manufacturer or wholesale distributor pursuant to subsection c. of this
section, shall be deemed confidential and shall not be disclosed to the public
or otherwise subject to public access, inspection, or copying, unless such
confidentiality is waived by the manufacturer or wholesale distributor.</p>

<p class=MsoNormal style='line-height:150%'>     g.    It shall not be a
defense to an action brought by the Attorney General pursuant to subsection d.
of this section that a manufacturer alleged to have violated P.L.    , c.   
(C.        ) (pending before the Legislature as this bill) did not sell the
essential off-patent or generic drug or biological product directly to a
consumer in this State.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    The Director of the
Division of Consumer Affairs in the Department of Law and Public Safety shall,
pursuant to the Administrative Procedure Act, P.L.1968, c.410
(C.52:14B-1&nbsp;et&nbsp;seq.)&nbsp;adopt such rules and regulations as shall
be necessary to implement the provisions of this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    This act shall take
effect the first day of the seventh month next following the date of enactment,
except that the Director of the Division of Consumer Affairs in the Department
of Law and Public Safety may take any advance administrative action as may be
necessary to implement the provisions of this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill prohibits
manufacturers and wholesale distributors of prescription drugs biological
products from excessively increasing the price of certain prescription drugs
and biological products without justification.</p>

<p class=MsoNormal style='line-height:150%'>     Specifically, manufacturers
and wholesale distributors may not engage in price gouging in the sale of an
essential off-patent or generic drug or biological product.  Price gouging is
defined to mean an increase in the price of a drug or biological product that: 
(1) is excessive and not justified by the cost of producing the drug or
biological product or expanding access to the drug or biological product to
promote the public health; and (2) results in consumers having no alternative
but to purchase the drug or biological product at an excessive price because of
the importance of the drug or biological product to their health and
insufficient marketplace competition.  Under the bill, wholesale distributors
will not be found to have violated this prohibition if the distributor
increases the price of a drug or biological product in direct response to
additional costs for the drug or biological product imposed on the distributor
by the manufacturer.</p>

<p class=MsoNormal style='line-height:150%'>     The bill defines essential
off-patent or generic drug or biological product to mean any prescription drug
or biological product, including any drug-device or biological product-device
combination product for the delivery of the prescription drug or biological
product:  (1) that is made available for sale in the State; (2) for which all
exclusive marketing rights granted under federal law have expired; (3) that is
actively manufactured and marketed by three or fewer manufacturers; and (4)
that appears on the current Model List of Essential Medicines adopted by the
World Health Organization or has been otherwise designated as an essential
medicine by the Commissioner of Health.</p>

<p class=MsoNormal style='line-height:150%'>     The Director of the Division
of Consumer Affairs in the Department of Law and Public Safety may notify the
Attorney General of any increase in the price of an essential off-patent or
generic drug or biological product whenever:  (1) the price increase,
individually or in combination with other price increases, would result in an
increase of 50 percent or more in the wholesale acquisition cost for the drug
or biological product or in the price paid for the drug or biological product
by the State Medicaid or NJ FamilyCare programs within a one-year period; and
(2) the wholesale acquisition cost of the drug or biological product is more
than $80 for a 30-day supply or a full course of treatment.</p>

<p class=MsoNormal style='line-height:150%'>     At the request of the Attorney
General, the manufacturer of an essential off-patent or generic drug or
biological product identified in a notice provided under the bill will be
required to submit, within 45 days of receiving the request, a statement to the
Attorney General:  (1) detailing the cost of producing the drug or biological
product; (2) identifying the circumstances and timing of any cost increases in
the preceding year; (3) identifying the circumstances and timing of any
expenditures made by the manufacturer to expand access to the drug or
biological product, and explaining any resulting improvements in public health;
and (4) any other information the manufacturer determines to be relevant to a
determination as to whether a violation of the provisions of the bill has
occurred.</p>

<p class=MsoNormal style='line-height:150%'>     The Attorney General may
require a manufacturer or a wholesale distributor to produce any records or
documents that may be relevant to a determination as to whether a violation of
the bill has occurred.  The Attorney General may additionally petition for a
court order compelling submission of any required statement or records;
restraining or enjoining a violation of the bill; restoring to any consumer, including
any third party payor, any money acquired by the manufacturer or wholesale
distributor as a result of a price increase that violates the bill; requiring a
manufacturer that has engaged in price gouging to make the drug or biological
product available in the State, for a period of up to one year, at a price that
does not exceed the price immediately prior to the violation; and assessing a
civil penalty of up to $10,000 against a manufacturer or wholesale distributor
who has violated the provisions of the bill.  For the purposes of assessing the
civil penalty, each sale of a drug or biological product at a price that
constitutes price gouging will be deemed a separate violation.  It will not be
a defense to an action brought by the Attorney General that a manufacturer did
not sell the essential off-patent or generic drug or biological product
directly to a consumer in New Jersey.</p>

<p class=MsoNormal style='line-height:150%'>     The Attorney General may not
commence an action seeking a court order for any relief, other than an order
compelling submission of required statements or records, unless the Attorney
General has provided the manufacturer or wholesale distributor the opportunity
to meet with the Attorney General to provide a justification for the price
increase.</p>

<p class=MsoNormal style='line-height:150%'>     Any information provided by a
manufacturer or wholesale distributor under the bill will be confidential and may
not be disclosed to the public or otherwise subjected to public access,
inspection, or copying, unless the manufacturer or wholesale distributor waives
confidentiality.</p>

</div>

</body>

</html>
